1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Orbifloxacin Solid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 50 Tuas West Drive
Singapore - Singapore 638408
Telephone: +1-908-740-4000
Emergency telephone number: 65 6697 2111 (24/7/365)
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity: Category 2

GHS label elements
Hazard pictograms: 

Signal word: Warning
Hazard statements: H361d Suspected of damaging the unborn child.
Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.
SAFETY DATA SHEET

Orbifloxacin Solid Formulation

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES


Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a
potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSOAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>PEL (long term)</td>
<td>10 mg/m³</td>
<td>SG OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Hand protection: Chemical-resistant gloves
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat.
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Colour: No data available
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies) Water solubility: No data available
Partition coefficient: n-
octanol/water
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

**Components:**

**Orbifloxacin:**
Acute oral toxicity
LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available
**SAFETY DATA SHEET**

**Orbifloxacin Solid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.12</td>
<td>27.08.2021</td>
<td>801089-00013</td>
<td>01.10.2020</td>
<td>15.07.2016</td>
</tr>
</tbody>
</table>

### Acute dermal toxicity

- Remarks: No data available

### Acute toxicity (other routes of administration)

- **LD50 (Rat):** > 200 mg/kg
  - Application Route: Intramuscular
  - **LD50 (Mouse):** 500 mg/kg
  - Application Route: Intramuscular
  - **LD50 (Rat):** 233 mg/kg
  - Application Route: Intravenous
  - **LD50 (Mouse):** 250 mg/kg
  - Application Route: Intravenous

### Magnesium stearate:

- **Acute oral toxicity**
  - **LD50 (Rat):** > 2,000 mg/kg
  - Method: OECD Test Guideline 423
  - Assessment: The substance or mixture has no acute oral toxicity
  - Remarks: Based on data from similar materials

- **Acute dermal toxicity**
  - **LD50 (Rabbit):** > 2,000 mg/kg
  - Remarks: Based on data from similar materials

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

**Orbifloxacin:**

- **Species:** Rabbit
- **Method:** Draize Test
- **Result:** No skin irritation

**Magnesium stearate:**

- **Species:** Rabbit
- **Result:** No skin irritation
- **Remarks:** Based on data from similar materials

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

**Orbifloxacin:**

- **Species:** Rabbit
- **Result:** Mild eye irritation
- **Method:** Draize Test

**Magnesium stearate:**

- **Species:** Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Orbifloxacin:**
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitiser.

**Magnesium stearate:**
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Orbifloxacin:**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative
Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Orbifloxacin:
Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Orbifloxacin:
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects, embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment:

Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:
Effects on fertility:

Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development:

Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Orbifloxacin:
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months  
Target Organs: Testis, Liver, Kidney, spleen

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>80 mg/kg</td>
<td>250 mg/kg</td>
<td>Oral</td>
<td>3 Months</td>
<td>Testis, Liver, Kidney, spleen</td>
<td>Gastrointestinal disturbance</td>
<td></td>
</tr>
</tbody>
</table>

Species: Juvenile dog  
NOAEL: 50 mg/kg  
LOAEL: 250 mg/kg  
Application Route: Oral  
Exposure time: 14 Days  
Target Organs: Heart, Bone  
Symptoms: Gastrointestinal disturbance  
Remarks: mortality observed

Species: Juvenile dog  
NOAEL: 2 mg/kg  
LOAEL: 3 mg/kg  
Application Route: Oral  
Exposure time: 90 Days  
Target Organs: Bone  
Remarks: No significant adverse effects were reported

Species: Dog  
NOAEL: 37.5 mg/kg  
Application Route: Oral  
Exposure time: 30 Days

Species: Cat  
NOAEL: 7.5 mg/kg  
LOAEL: 22.5 mg/kg  
Application Route: Oral  
Exposure time: 1 Month  
Symptoms: Gastrointestinal disturbance

**Magnesium stearate:**
Species: Rat  
NOAEL: > 100 mg/kg  
Application Route: Ingestion  
Exposure time: 90 Days  
Remarks: Based on data from similar materials

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Orbifloxacin:**
Ingestion: Symptoms: central nervous system effects, Gastrointestinal
disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Magnesium stearate:

<table>
<thead>
<tr>
<th>Toxicity to fish</th>
<th>LC50 (Leuciscus idus (Golden orfe)): &gt; 100 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>48 h</td>
</tr>
<tr>
<td>Method</td>
<td>DIN 38412</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Toxicity to daphnia and other aquatic invertebrates:

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>EL50 (Daphnia magna (Water flea)): &gt; 1 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure</td>
<td>47 h</td>
</tr>
<tr>
<td>Test substance</td>
<td>Water Accommodated Fraction</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

Toxicity to algae/aquatic plants:

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>EL50 (Pseudokirchneriella subcapitata (green algae)): &gt; 1 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure</td>
<td>72 h</td>
</tr>
<tr>
<td>Test substance</td>
<td>Water Accommodated Fraction</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>NOELR</td>
<td>Pseudokirchneriella subcapitata (green algae): &gt; 1 mg/l</td>
</tr>
<tr>
<td>Exposure</td>
<td>72 h</td>
</tr>
<tr>
<td>Test substance</td>
<td>Water Accommodated Fraction</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Toxicity to microorganisms:

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>EC10 (Pseudomonas putida): &gt; 100 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure</td>
<td>16 h</td>
</tr>
<tr>
<td>Test substance</td>
<td>Water Accommodated Fraction</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Persistence and degradability

Components:

Magnesium stearate:

Biodegradability:

<table>
<thead>
<tr>
<th>Result</th>
<th>Not biodegradable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Bioaccumulative potential

Components:

Magnesium stearate:
13. DISPOSAL CONSIDERATIONS

Disposal methods
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable

IATA-DGR
- UN/ID No.: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- Packing instruction (cargo aircraft): Not applicable
- Packing instruction (passenger aircraft): Not applicable

IMDG-Code
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- EmS Code: Not applicable
- Marine pollutant: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Special precautions for user
Not applicable
15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)


ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-
SAFETY DATA SHEET

Orbifloxacin Solid Formulation

Version 1.12  Revision Date: 27.08.2021  SDS Number: 801089-00013  Date of last issue: 01.10.2020
Date of first issue: 15.07.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

SG / EN